ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 200 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei),serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - posaconazole 100 mg - posaconazole

ישראל - עברית - Ministry of Health

ofek pharma ltd, israel - posaconazole - טבליות שחרור מושהה - posaconazole 100 mg - posaconazole

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - caspofungin as acetate - אבקה להכנת תמיסה מרוכזת לעירוי - caspofungin as acetate 50 mg/vial - caspofungin - caspofungin - cancidas is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). cancidas has not been studied as initial therapy for invasive aspergillosis.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - caspofungin as acetate - אבקה להכנת תמיסה מרוכזת לעירוי - caspofungin as acetate 70 mg/vial - caspofungin - caspofungin - cancidas is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). cancidas has not been studied as initial therapy for invasive aspergillosis.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תמיסה לאינפוזיה - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.